Le Méridien Vaccine (06660.HK) received 400 additional H shares by Zhou Yan, worth approximately HK$3,328
On May 3, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 3, Zhou Yan increased her H shares of $Aimei Vaccine (06660.HK) by $400 at an average price of HK$8.32 per share on April 26, worth about HK$3,328. After the increase in holdings, Zhou Yan's latest shareholding was 24.5816 million shares, with a good position ratio of 4.99%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors and top executives of listed companies are required
Xiansheng Pharmaceutical (02096) spent HK$781,600 to buy back 138,000 shares on May 3
According to the Zhitong Finance App, Xiansheng Pharmaceutical (02096) announced that on May 3, 2024, the company spent HK$781,600 to repurchase 138,000 shares at a repurchase price of HK$5.64-5.67 per share.
CSPC Group (01093.HK) cancelled 26.628 million shares on May 3
Gelonghui, May 3, 丨 Shiyao Group (01093.HK) announced that on May 3, 2024, 26.628 million shares have been cancelled.
CCB International: Maintaining Cinda Biotech's (01801) “Outperform the Market” rating and raising the target price to HK$54.7
According to CCB International, Cinda Biotech (01801) is one of the bank's preferred stocks in the Chinese pharmaceutical industry.
Hong Kong Stock Concept Tracking | China's Nuclear Medicine Industry Attracts Attention (with concept stocks), the key technology for batch online irradiation production of isotopes
Various short-half-life medical isotopes that are currently in short supply in China will enter the large-scale production stage after the supporting plant is completed and put into operation in the second half of this year.
Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop
Antengene's (HKG:6996) attributable loss narrowed to 581.2 million yuan, or 0.94 yuan per share, in 2023 from 601.5 million yuan, or 0.97 yuan per share, in 2022, according to the company's annual rep